Pertinax Pharma are a medical device company based in Bristol, UK. We make innovative antimicrobial technologies for use in medical devices.
Our patented materials can be incorporated into a wide range of medical device material substrates, including polymers and coatings. The technology works by gradually and steadily releasing chlorhexidine, a well known antiseptic material, thus protecting against infection. A key aspect of our technology offering is that it is antibiotic-free, meaning that it does not contribute to the growth of antibiotic resistance. We see the opportunity to develop anti-infective medical devices that help stem the spread of resistant bacteria as the driving force behind our products.
Meet the team
Dr Michele Barbour, Chief Executive Officer,has overall responsibility for strategic direction of the company. She is the inventor of Pertinax technology and is also a respected academic in the field of biomaterials and has published over 50 peer-reviewed publications.
Simon Hubbert, Chairman, has over 25 years’ experience in the medical device industry and has held CEO, senior commercial and general management position in both public and private global medtech companies including Johnson & Johnson, Medtronic, Lombard Medical and LMA International.
Stuart Gibson, Chief Financial Officer, is an experienced CFO who since 2001 has focused on early stage biotech and technology companies. During his career he has been involved in a significant number of corporate finance and M&A transactions, an IPO and a wide range of international commercial deals.
Dr Chris Nicklin, Technical Operations Consultant, provides technical and operations support for Pertinax, drawing on over 25 years’ experience in the Pharmaceutical and Fine Chemical sectors and his experience with multiple early stage biotech companies engaged in chemical development, scale-up, technology transfer and manufacturing.
Research and Development Team. The management team are supported by a team of dynamic and versatile scientists who manufacture, characterise, analyse and carry out proof of concept studies illustrating the use of Pertinax in various materials and devices. Our labs permit a range of chemical, physical and biological analysis to be carried out efficiently in house, and we can also perform such analysis under contract for customers and partners.
The company is funded by a combination of equity-based investment and public grant money. If you are or represent an investor and are interested in learning more about investment opportunities, contact us.